1. Home
  2. XFOR vs OPOF Comparison

XFOR vs OPOF Comparison

Compare XFOR & OPOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • OPOF
  • Stock Information
  • Founded
  • XFOR 2014
  • OPOF 1922
  • Country
  • XFOR United States
  • OPOF United States
  • Employees
  • XFOR N/A
  • OPOF 293
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • OPOF Major Banks
  • Sector
  • XFOR Health Care
  • OPOF Finance
  • Exchange
  • XFOR Nasdaq
  • OPOF Nasdaq
  • Market Cap
  • XFOR 118.4M
  • OPOF 151.3M
  • IPO Year
  • XFOR N/A
  • OPOF N/A
  • Fundamental
  • Price
  • XFOR $0.47
  • OPOF $29.80
  • Analyst Decision
  • XFOR Strong Buy
  • OPOF
  • Analyst Count
  • XFOR 3
  • OPOF 0
  • Target Price
  • XFOR $3.50
  • OPOF N/A
  • AVG Volume (30 Days)
  • XFOR 6.8M
  • OPOF 5.3K
  • Earning Date
  • XFOR 03-20-2025
  • OPOF 01-30-2025
  • Dividend Yield
  • XFOR N/A
  • OPOF 1.88%
  • EPS Growth
  • XFOR N/A
  • OPOF 22.03
  • EPS
  • XFOR N/A
  • OPOF 1.88
  • Revenue
  • XFOR $1,123,000.00
  • OPOF $60,914,000.00
  • Revenue This Year
  • XFOR N/A
  • OPOF N/A
  • Revenue Next Year
  • XFOR $590.67
  • OPOF N/A
  • P/E Ratio
  • XFOR N/A
  • OPOF $15.87
  • Revenue Growth
  • XFOR N/A
  • OPOF 2.43
  • 52 Week Low
  • XFOR $0.26
  • OPOF $13.49
  • 52 Week High
  • XFOR $1.60
  • OPOF $30.10
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 41.75
  • OPOF 84.60
  • Support Level
  • XFOR $0.46
  • OPOF $24.90
  • Resistance Level
  • XFOR $0.54
  • OPOF $30.10
  • Average True Range (ATR)
  • XFOR 0.05
  • OPOF 0.57
  • MACD
  • XFOR -0.01
  • OPOF 0.52
  • Stochastic Oscillator
  • XFOR 5.63
  • OPOF 94.88

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About OPOF Old Point Financial Corporation

Old Point Financial Corp functions in the financial services domain in the United States. As the holding company of The Bank and Trust, it is a nationally chartered trust and wealth management service, provider. Its suite of services includes commercial banking solutions such as loan, deposit and cash management, which are rendered through a chain of branches throughout the country. It operates through segments such as Bank, Wealth and Company.

Share on Social Networks: